Millions of People around the World… Are Waiting for Solutions

Madam, Sir, Dear investors,

Affluent Medical develops innovative prostheses, at a clinical stage, to treat urinary incontinence and mitral cardiac insufficiency.

Millions of people around the world are affected by these diseases, reducing their quality and life expectancy. Urinary incontinence affects more than 100 million adults over the age of 20 worldwide on its moderate to severe form1 and mitral cardiac insufficiency is a disease that affects more than 2% of the world’s population.Our goal is to offer a solution to these millions of patients by developing innovative medical protheses, which have already demonstrated their effectiveness in pre-clinical and clinical studies.

These mini-invasive medical devices also have the advantage of simplifying the surgical procedure and reducing health care costs for the patient and for public health systems.

Our product portfolio now includes 3 innovative prostheses and one technology protected by 31 patent families in all our markets:

• Artus: the first artificial sphincter that patients can activate via a remote control, for the treatment of moderate to severe urinary incontinence in men and women;
• Kalios: the only prosthesis for mitral heart valve repair that allows for multiple post-operative readjustments via a transcatheter procedure without general anaesthesia;
• Epygon: the only physiological cardiac bioprosthesis that mimics the native mitral valve and blood flow and can be implanted via minimally invasive procedures without an “open heart” surgery.

Initial development stages have been completed for these three products with major investments made and positive pre-clinical and clinical results already obtained.

In these fast-growing markets, particularly driven by longer lifespans, our industrial and commercial strategy will be based on own sales forces in key European countries (Germany, France, Italy, UK) and on commercial agreements with strategic partners and local distributors in the United States, China and the rest of Europe.

Our IPO will allow our medical devices to be quickly marketed with the first revenues generated from the sales of Kalios in Europe expected as early as 2024, after obtaining regulatory approvals.

We hope that this ambitious project, which aims to improve the quality and life expectancy of millions of patients worldwide, will convince you and that we will soon be able to count you among our shareholders.